Treating COVID-19 infection with molnupiravir can lead to quicker recovery at home thelancet TheLancet
Molnupiravir does not reduce hospital admissions or deaths in vaccinated adults with COVID-19 infection who are at higher risk of mortality, according to the results of a randomized controlled trial, published injournal. However, the patients treated at home with molnupiravir recovered quicker compared to the control group.
"Although this trial found no benefit from molnupiravir treatment on its primary outcome—which hypothesized that treatment with molnupiravir for vaccinated, at-risk patients would reduce the likelihood of hospitalization or death—the trial suggests that this treatment could have other benefits when being used to treat COVID-19, such as a fasterhealth services
Patients had a confirmed omicron COVID-19 infection and were unwell for five days or less before beginning treatment. The results represent outcomes for patients treated between 8th December 2021 and 27th April 2022, during the peak of the omicron wave in the UK. Participants receiving molnupiravir reported more favorable outcomes for a variety of the secondary outcomes in this study. The median average length of illness in patients who took molnupiravir was nine days compared to 15 days in the control group. Using statistical modeling that accounted for the range of recovery times across both groups, the authors found that patients taking molnupiravir recovered an average of 4.2 days quicker compared to patients in the control group.
"Therefore, our study contributes to the valuable evidence base on who should not be treated with these precious, newly discovered agents, to empower clinicians to make decisions led by robust evidence when prescribing treatments for COVID-19 infections," says study co-author, Professor Ly-Mee Yu, University of Oxford, UK.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Most common Covid symptoms as cases rise & you might confuse them for a coldAS Christmas approaches, no one wants to be struck down with illness. With many people currently battling with a cough or a sniffle, it can be easy to dismiss your symptoms as a cold. That’s …
Lire la suite »
Covid, cold, flu, Strep A and RSV symptoms - how to tell winter lurgies apartWinter is prime time for many different illnesses to spread around, so here are all the differences between symptoms.
Lire la suite »
Latest Covid symptoms as cases surge 25% before ChristmasLatest Covid symptoms as cases surge 25% ahead of Christmas
Lire la suite »
China’s Fast And Deadly Road To Covid Recovery | OilPrice.comChina has officially pivoted from its zero-Covid policy, meaning it is now just a question of time before it ‘exits’ Covid and its oil demand rebounds
Lire la suite »
China’s Covid Deaths Could Be Above 5,000 Per Day | OilPrice.comAccording to health data firm Airfinity, more than 5,000 people are probably dying each day from COVID-19 in China, with the firm’s mortality risk analysis suggesting that 1.3 to 2.1 million people could die in the country’s current COVID outbreak.
Lire la suite »
Loss of Y in leukocytes as a risk factor for critical COVID-19 in men - Genome MedicineBackground The COVID-19 pandemic, which has a prominent social and economic impact worldwide, shows a largely unexplained male bias for the severity and mortality of the disease. Loss of chromosome Y (LOY) is a risk factor candidate in COVID-19 due to its prior association with many chronic age-related diseases, and its impact on immune gene transcription. Methods Publicly available scRNA-seq data of PBMC samples derived from male patients critically ill with COVID-19 were reanalyzed, and LOY status was added to the annotated cells. We further studied LOY in whole blood for 211 COVID-19 patients treated at intensive care units (ICU) from the first and second waves of the pandemic. Of these, 139 patients were subject to cell sorting for LOY analysis in granulocytes, low-density neutrophils (LDNs), monocytes, and PBMCs. Results Reanalysis of available scRNA-seq data revealed LDNs and monocytes as the cell types most affected by LOY. Subsequently, DNA analysis indicated that 46%, 32%, and 29% of critically ill patients showed LOY above 5% cut-off in LDNs, granulocytes, and monocytes, respectively. Hence, the myeloid lineage that is crucial for the development of severe COVID-19 phenotype is affected by LOY. Moreover, LOY correlated with increasing WHO score (median difference 1.59%, 95% HDI 0.46% to 2.71%, p=0.025), death during ICU treatment (median difference 1.46%, 95% HDI 0.47% to 2.43%, p=0.0036), and history of vessel disease (median difference 2.16%, 95% HDI 0.74% to 3.7%, p=0.004), among other variables. In 16 recovered patients, sampled during ICU stay and 93–143 days later, LOY decreased significantly in whole blood and PBMCs. Furthermore, the number of LDNs at the recovery stage decreased dramatically (median difference 76.4 per 10,000 cell sorting events, 95% HDI 55.5 to 104, p=6e−11). Conclusions We present a link between LOY and an acute, life-threatening infectious disease. Furthermore, this study highlights LOY as the most prominent clonal mutation affe
Lire la suite »